Recorlev Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918984 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 5 months from now)

US11478471 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 5 months from now)

US10835530 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 5 months from now)

US10517868 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 5 months from now)

US10098877 STRONGBRIDGE Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Jan, 2026

(1 year, 5 months from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11903940 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)

US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(15 years from now)



Recorlev is a drug owned by Strongbridge Dublin Ltd. It is used for treating Cushing's syndrome in patients with endogenous hypercortisolemia, when surgery is not an option or has not been curative. Recorlev uses Levoketoconazole as an active ingredient. Recorlev was launched by Strongbridge in 2021. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 02, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-385) Dec 30, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative; During levoketoconazole dosage titration for the treatment of ...

Dosage: TABLET

More Information on Dosage

RECORLEV family patents

Family Patents